UNSPSC 51162733: Prenisteine

This classification denotes a mucolytic agent with the molecular formula C8H15NO2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 99TA452185, chemically known as l-alanine, 3-((3-methyl-2-butenyl)thio)- but more generally known as prenisteine, which bears US NIH Compound Identifier 21359. European Medicines Agency schedules Prenisteine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10028MIG. The term PRENISTEINE is an International Non-Proprietary Name.

UNSPSC 51162733 Prenisteine, a Commodity code, covers parenteral pharmaceutical products and related healthcare supplies that state and local governments procure for correctional facilities, public health departments, and other medical service providers. State and local buyers under this code source intravenous nutrition solutions (total parenteral nutrition and peripheral parenteral nutrition), IV solutions, naloxone, drug deactivation systems, and other parenteral products required to deliver medically necessary care to incarcerated individuals and community populations. Issuing bodies include state departments of corrections, county health departments, and other public agencies managing inmate and community health programs. Solicitations emphasize rapid delivery cycles—some requiring fulfillment within 8 to 24 hours of order—and strict compliance with state licensing, background clearance, and insurance requirements including professional liability and cyber liability coverage.

Recent activity shows Washington State Department of Corrections (RFQQK13020, RFQ due October 7, 2026) procuring parenteral products and services across eight correctional facilities in three regions, with DOC potentially awarding up to three contractors per region and contract terms running November 26, 2026 through June 30, 2030. Seminole County, Florida (IFB60459723LAS, IFB with a historical due date of July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. The Washington solicitation incorporates state set-aside targets for small, minority-owned, women-owned, and veteran-owned businesses under Chapter 39.19 RCW, with an aspirational 5% Small and Diverse Business Goal and subcontractor inclusion requirements. Geographic activity centers on Washington and Florida, with scope spanning correctional healthcare systems and community public health procurement.